A Role for Focal Adhesion Kinase in Phenylephrine-induced Hypertrophy of Rat Ventricular Cardiomyocytes
Overview
Authors
Affiliations
A variety of agonists including phenylephrine (PE) induce hypertrophy in neonatal ventricular cardiomyocytes. Here we report that signals provided by extracellular matrix proteins (ECM) augment the PE-induced hypertrophic response of cardiomyocytes and provide evidence that ECM-dependent signaling is mediated in part by the protein tyrosine kinase, focal adhesion kinase (FAK). Addition of PE to cultured neonatal cardiomyocytes stimulated sarcomeric organization, increased cell size, and induced atrial natriuretic factor in cardiomyocytes plated on the ECM protein laminin or fibronectin. In contrast, cardiomyocytes plated on the non-adhesive substrate gelatin exhibited a reduced capacity to undergo these PE-stimulated hypertrophic changes. In cardiomyocytes cultured on ECM, PE stimulated a rapid increase in tyrosine phosphorylation of focal adhesion proteins including FAK, paxillin, and p130 Crk-associated substrate and subsequent formation of peripheral focal complexes. Inhibition of the PE-induced hypertrophic response by genistein and herbimycin-A indicated a requirement for protein tyrosine kinases in PE signaling. To determine whether activation of FAK is required for PE-induced hypertrophy, a dominant-interfering mutant form of FAK, termed FRNK (FAK-related non-kinase), was ectopically expressed in cardiomyocytes using a replication-defective adenovirus expression system. FRNK expression attenuated PE-stimulated hypertrophy as assessed by cell size, sarcomeric organization, and induction of atrial natriuretic factor. These data indicate that the signal transduction pathways leading to cardiomyocyte hypertrophy are strongly influenced by and/or dependent upon an integrin-mediated signaling process requiring FAK.
Li G, Pan B, Liu L, Xu X, Zhao W, Mou Q Mol Cell Biochem. 2023; 479(4):963-973.
PMID: 37266748 DOI: 10.1007/s11010-023-04768-2.
Migfilin: Cell Adhesion Effect and Comorbidities.
Duan B, Qin Z, Gu X, Li Y Onco Targets Ther. 2022; 15:411-422.
PMID: 35469339 PMC: 9034862. DOI: 10.2147/OTT.S357355.
AZD2014, a dual mTOR inhibitor, attenuates cardiac hypertrophy in vitro and in vivo.
Cha B, Jung M, Kim A, Lepak V, Colson B, Bull D J Biol Eng. 2021; 15(1):24.
PMID: 34674743 PMC: 8529824. DOI: 10.1186/s13036-021-00276-3.
Integrins in cardiac hypertrophy: lessons learned from culture systems.
Bildyug N ESC Heart Fail. 2021; 8(5):3634-3642.
PMID: 34232557 PMC: 8497369. DOI: 10.1002/ehf2.13497.
Lin K, Kumar V, Shanmugam T, Shibu M, Chen R, Kuo C Mol Cell Biochem. 2021; 476(9):3253-3260.
PMID: 33886061 DOI: 10.1007/s11010-021-04100-w.